

# KX2-391

**Catalog No: tcsc0248**



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

897016-82-9

**Formula:**

$C_{26}H_{29}N_3O_3$

**Pathway:**

Protein Tyrosine Kinase/RTK;Cell Cycle/DNA Damage;Cytoskeleton

**Target:**

Src;Microtubule/Tubulin;Microtubule/Tubulin

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Alternative Names:**

KX-01

**Observed Molecular Weight:**

431.53


## Product Description

KX2-391 is an inhibitor of **Src** that targets the peptide substrate site of Src, with **GI<sub>50</sub>** of 9-60 nM in cancer cell lines.

IC50 & Target: GI50: 9 nM (Src, in HuH7 cells), 13 nM (Src, in PLC/PRF/5 cells), 26 nM (Src, in Hep3B cells), 60 nM (Src, in HepG2 cells)  
 [1]

**In Vitro:** KX2-391 is a Src inhibitor that is directed to the Src substrate pocket. KX2-391 shows steep dose-response curves against Huh7 (GI<sub>50</sub>=9 nM), PLC/PRF/5 (GI<sub>50</sub>=13 nM), Hep3B (GI<sub>50</sub>=26 nM), and HepG2 (GI<sub>50</sub>=60 nM), four hepatic cell cancer (HCC) cell lines [1]. KX2-391 is found to inhibit certain leukemia cells that are resistant to current commercially available drugs, such as those derived from chronic leukemia cells with the T3151 mutation. KX2-391 is evaluated in engineered Src driven cell growth assays in NIH3T3/c-Src527F and SYF/c-Src527F cells and exhibits GI<sub>50</sub> with 23 nM and 39 nM, respectively [2].

**In Vivo:** Orally administered KX2-391 is shown to inhibit primary tumor growth and to suppress metastasis, in pre-clinical animal models of cancer [2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!